Compositions and methods for reducing or preventing metastasis
Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
1. A method for reducing or preventing metastasis development in a subject following a tumor excision surgery, the method comprising the step of administering to the subject a pharmaceutical composition comprising glucopyranosyl lipid adjuvant (GLA) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein said administration is effective in reducing or preventing metastasis, and wherein said administering is carried out during the perioperative period of said tumor excision surgery.
2. The method of claim 1 , wherein said administering is by local-regional delivery.
3. The method of claim 1 , wherein said pharmaceutical composition is substantially devoid of a cancer-antigen.
4. The method of claim 1 , wherein said administering is carried out at least one time before the surgery (pre-operative).
5. The method of claim 1 , wherein said administering is carried out at least one time after the surgery (post-operative).
6. The method of claim 1 , wherein said pharmaceutic composition is administered in constant doses.
7. The method of claim 1 , wherein said pharmaceutic composition is administered in varying doses.
8. The method of claim 1 , wherein GLA has the following structural formula (I):
wherein:
R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl; and R 2 and R 4 are C 12 -C 20 alkyl.
9. The method of claim 8 , wherein R 1 , R 3 , R 5 and R 6 are undecyl and R 2 and R 4 are tridecyl.
10. The method of claim 1 , wherein GLA has the following structural formula (II):
wherein:
L 1 , L 2 , L 3 , L 4 , L 5 and L 6 are the same or different and independently —O—, —NH— or —(CH 2 )—;
L 7 , L 8 , L 9 , and L 10 are the same or different and independently absent or —C(═O)—;
Y 1 is an acid functional group;
Y 2 and Y 3 are the same or different and independently —OH, —SH, or an acid functional group;
Y 4 is —OH or —SH;
R 1 , R 3 , R 5 and R 6 are the same or different and independently C 8 -C 13 alkyl; and
R 2 and R 4 are the same or different and independently C 6 -C 11 alkyl.
11. The method of claim 10 , wherein GLA has the following structure:
12. The method of claim 1 , further comprising the step of administering a beta-adrenergic blocker, a COX2 inhibitor, or both.
13. The method of claim 12 , wherein said further administering is carried out during the perioperative period of a tumor excision surgery.
14. The method of claim 12 , wherein the beta-adrenergic blocker and COX2 inhibitor are present within separate pharmaceutical compositions.
15. The method of claim 13 , wherein the beta-adrenergic blocker, COX2 inhibitor or both are administered at least one time before the surgery (pre-operative).
16. The method of claim 13 , wherein beta-adrenergic blocker, COX2 inhibitor or both are administered at least one time after the surgery (post-operative).
17. The method of claim 13 , wherein administering said pharmaceutical composition and further administering of a beta-adrenergic blocker, COX2 inhibitor, or both are carried out on the same days during the perioperative period.
18. The method of claim 13 , wherein administering said pharmaceutical composition and further administering of a beta-adrenergic blocker, COX2 inhibitor, or both are carried out on separate days during the perioperative period.
19. The method of claim 12 , wherein the beta-adrenergic blocker is selected from the group consisting of acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, metoprolol, nadolol, nebivolol, oxyprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, and pharmaceutically acceptable salts thereof.
20. The method of claim 19 , wherein the beta-adrenergic blocker is propranolol or a pharmaceutically acceptable salt thereof.
21. The method of claim 12 , wherein the COX2 inhibitor is selected from the group consisting of celecoxib, cimicoxib, etoricoxib, etodolac, eoricoxib, lumiracoxib, meloxicam, parecoxib, rofecoxib, tiracoxib, valdecoxib, and pharmaceutically acceptable salts thereof.
22. The method of claim 21 , wherein the COX2 inhibitor is etodolac or a pharmaceutically acceptable salt thereof.